Development of disease-specific treatments based on pathophysiology of polycystic kidney disease with a focus on tissue transglutaminase

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K08162
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 52050:Embryonic medicine and pediatrics-related
• Research Institution: University of the Ryukyus
• Principal Investigator: Nakanishi Koichi 琉球大学, 医学(系)研究科(研究院), 教授 (50336880)
• Co-Investigator(Kenkyū-buntansha): 島 友子 和歌山県立医科大学, 医学部, 講師 (60433364)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: 多発性嚢胞腎 / 上皮間葉移行 / 増殖 / 分泌 / 細胞外基質 / 組織トランスグルタミナーゼ / miRNA

Outline of Final Research Achievements

The purpose of this study is to elucidate the involvement of tissue transglutaminase in multiple basic pathophysiologies of polycystic kidney disease (PKD) and its mechanisms, to obtain basic knowledge for the development of pathophysiology-based disease-specific therapies by modifying them, and to confirm their efficacy in humans by using animal models for their application. The research is to confirm the efficacy of the treatment by using model animals for its application to humans.
Until R3, we have been analyzing the pathophysiology of ARPKD by focusing on the relationship between tissue transglutaminase expression in cultured PKD cell lines and ARPKD animal model-derived tissues and the miRNA data accumulated so far in the ARPKD model.
In R4, we are further analyzing the data by real-time PCR, Western blotting, and immunostaining.

Free Research Field

遺伝性腎疾患

Academic Significance and Societal Importance of the Research Achievements

多発性嚢胞腎の複数の基本的病態生理における組織トランスグルタミナーゼの関与とその機序が解明され、それらを修飾することによる病態生理に基づいた疾患特異的治療開発のための基礎的知見が獲得され、そのヒトへの応用のためのモデル動物を用いた治療研究による効果が確認されれば、新しい治療法の開発に繋がる可能性があり、医学・医療に貢献する。